Bluejay Diagnostics Announces Federal Distribution Partnership with Lovell

What Happened
Bluejay Diagnostics, Inc. (BJDX) filed a Form 8-K on September 8, 2026 reporting that on September 1, 2026 it entered a Distribution, Co‑Marketing & Strategic Partnership Agreement with Lovell Government Services, Inc., an SDVOSB federal healthcare distributor. The agreement gives Lovell a non‑exclusive right to resell Bluejay products on open-market federal, state and local procurements and a sole, exclusive right to distribute Bluejay products for federal procurements that require or favor SDVOSB set‑aside status (e.g., VA, DoD, IHS). Distribution to federal healthcare customers is conditioned on applicable FDA clearance or other required regulatory authorization.

Key Details

• Agreement date: September 1, 2026; 8‑K filed September 8, 2026.
• Financials/fees: one‑time discounted setup fee of $5,500; Lovell earns ~15% distribution fee on gross sales (added to Company’s cost of goods sold per the agreement) and an additional 2% fee on sales through Lovell catalogs listed with DAPA prime vendors.
• Payment & pricing: Lovell must remit payment to Bluejay within 3 business days after receiving payment from the government (or within 30 days after receiving a valid invoice). Company may change product prices with written notice but must give Lovell at least 90 days’ notice for increases; up to two price increase requests per calendar year. Undisputed late amounts accrue interest at the lesser of 18% per year or the maximum allowed by law.
• Term & termination: initial two‑year term with automatic one‑year renewals unless 90 days’ notice is given. Either party can terminate immediately for suspension/exclusion from healthcare programs, certain criminal convictions, bankruptcy, a final judgment over $100,000 that materially impairs performance, or permanent discontinuation; 30‑day cure period for other defaults.

Why It Matters
The agreement gives Bluejay a dedicated federal distribution channel—including exclusive access for SDVOSB set‑aside opportunities—once regulatory clearance is obtained, which could help the company pursue VA/DoD/IHS contracts and grow government revenue. The ~15% fee structure and the statement that that fee is added to cost of goods sold are material details for gross margin and revenue recognition assumptions. Payment terms may accelerate cash receipts when sales occur through Lovell. Investors should note the exclusivity applies only to SDVOSB set‑asides (not all federal procurements) and that federal sales are contingent on FDA clearance or other required authorizations. A press release regarding the agreement was also filed with the 8‑K.